A coronary stent cannot be used when a patient’s blood vessels are too diseased or too small to hold one, when required blood-thinning medications would be too dangerous, or when the overall complexity of heart disease makes bypass surgery a better option. These aren’t rare edge cases. A significant number of people evaluated for stenting end up needing a different approach, whether that’s open-heart surgery, medication alone, or a combination of both.
Blood Thinners You Can’t Safely Take
After a stent is placed, you need to take two blood-thinning medications (called dual antiplatelet therapy) for months to prevent blood clots from forming inside the stent. If you can’t safely take these drugs, a stent is generally off the table. The most common reasons include active bleeding in the stomach or intestines, a recent bleeding stroke, or a known bleeding disorder like hemophilia. Severe anemia or very low platelet counts also raise the risk of dangerous bleeding during and after the procedure.
Aspirin intolerance is surprisingly common among people who need stenting. In one study of patients who couldn’t take aspirin, roughly half had gastrointestinal problems, about 40% had true allergies, and the rest had other bleeding issues. Alternative drug combinations exist for some of these patients, but they aren’t always a reliable substitute, and doctors weigh the risks carefully before proceeding.
Arteries Too Small or Too Damaged
Stents are physical devices that need a minimum amount of space to work. Arteries smaller than 2.5 millimeters in diameter carry a significantly higher risk of failure after stenting, including re-narrowing and serious cardiovascular events. Below 2.0 millimeters, placing a stent becomes technically impossible or risks rupturing the vessel entirely. These very small arteries are typically treated with medication or, in some cases, a balloon procedure without a stent.
Heavy calcification is another dealbreaker. When plaque has hardened into calcium deposits along the artery wall, the stent may not expand properly or adhere to the vessel. This leads to complications or re-narrowing. Similarly, arteries with extreme twisting or tortuosity can block the delivery system that threads the stent into position, making the procedure too risky to attempt. Coronary anatomy with many branch points and severe angles presents the same challenge.
Disease Too Widespread for Stenting
When blockages are scattered across multiple arteries or stretch along long segments of a vessel, stenting becomes impractical. Doctors use a scoring system called the SYNTAX score to assess how complex the disease is. The scale runs from 0 to above 32, with higher numbers reflecting more complicated anatomy.
For patients with low scores (22 or below), stenting and bypass surgery produce similar survival rates over 10 years. But once the score climbs above 22, bypass surgery offers a clear survival advantage. Patients with high SYNTAX scores (above 32) who received stents instead of bypass had roughly 86% higher 10-year mortality. Current American and European cardiology guidelines recommend bypass surgery for intermediate and high-complexity multivessel disease, reserving stenting for simpler cases.
Chronic Total Occlusions
A chronic total occlusion is an artery that has been completely blocked for at least three months. While experienced centers can reopen these arteries with stenting about 90% of the time, the procedure carries a much higher complication rate than standard stenting, particularly a greater risk of puncturing the artery wall. Patients most likely to fail the procedure tend to be older, have reduced heart function, and have heavily calcified blockages across multiple vessels.
Whether reopening a totally blocked artery is even worthwhile depends on whether the heart muscle it feeds is still alive. If the tissue has already scarred over from lack of blood flow, restoring circulation to that area won’t improve heart function or survival. Guidelines emphasize testing for viable heart muscle before attempting these high-risk procedures.
Kidney Function and Contrast Dye
Stent placement requires injecting contrast dye so the cardiologist can see the arteries on imaging. This dye is processed by the kidneys, and for people with severely reduced kidney function, it can trigger acute kidney injury. The threshold that raises concern is a filtration rate (eGFR) below 30, which corresponds to severe kidney disease. Above 45, the risk from modern contrast dye is essentially no different from not receiving it at all. Between 30 and 45, the picture is less clear, and doctors take extra precautions like hydration protocols.
No specific kidney function level makes contrast dye absolutely prohibited, but patients already on dialysis or near that stage face a risk-benefit calculation that may tip against stenting, particularly for non-emergency situations.
Metal Allergies
Most coronary stents contain nickel, and roughly 10% of the general population has some degree of nickel sensitivity. The rate is higher in women, between 14% and 20%, largely due to sensitization from pierced jewelry. The FDA has warned against stent implantation in patients with known metal allergies, and there are case reports of stent reactions severe enough to require device removal.
In practice, however, the clinical significance remains debated. Many cardiologists do not routinely test for nickel allergy before placing stents, and large studies have not found a strong link between nickel sensitivity and stent failure. For patients with a documented, severe metal allergy who need a stent, newer polymer-coated stents or bioresorbable scaffolds that dissolve over time may be options worth discussing.
When Medication Alone Works Just as Well
For people with stable coronary artery disease, meaning chest pain that’s predictable and manageable rather than a heart attack in progress, stenting may simply not be necessary. The landmark ISCHEMIA trial enrolled over 5,000 patients with moderate to severe blockages and randomly assigned them to either stenting (or bypass) plus medication, or medication alone. After a median of 3.2 years, the rates of heart attack, death, and other major cardiac events were nearly identical between the two groups. At five years, the difference was less than two percentage points.
Deaths were virtually the same: 145 in the stenting group versus 144 in the medication-only group. This doesn’t mean stents are useless. They remain critical during heart attacks and for people whose symptoms don’t respond to medication. But for stable disease, modern drug therapy with cholesterol-lowering, blood pressure, and antiplatelet medications can match the outcomes of an invasive procedure, without the procedural risks, recovery time, or need for prolonged dual blood thinners.
Limited Life Expectancy
Stenting is meant to prevent future heart events and improve quality of life over months to years. For patients with terminal cancer, end-stage organ failure, or other conditions that severely limit life expectancy, the risks of the procedure and the burden of required medications afterward often outweigh whatever benefit the stent might provide. In these cases, managing symptoms with medication alone is typically the more appropriate path.